+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Clinuvel Pharmaceuticals Ltd (CUV) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 44 Pages
  • October 2023
  • GlobalData
  • ID: 1322573
Clinuvel Pharmaceuticals Ltd (CUV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) is a biopharmaceutical company that focuses on the development of drugs for the treatment of light-related severe skin disorders. The company’s lead product candidate, Scenesse (afamelanotide) is a first-in-class drug targeting erythropoietic protoporphyria (EPP) and is approved in Europe, Australia and the US for treating adult EPP patients. Its other pipeline products include CUV9900 and VLRX001 among others. Clinuvel Pharmaceuticals also focused on developing a pediatric formulation of Scenesse for EPP and OTC products for general photoprotective application. The company through its subsidiaries has operations in Australia, Switzerland, Ireland, the UK, the US, and Singapore. Clinuvel Pharmaceuticals is headquartered in Melbourne, Victoria, Australia.

Clinuvel Pharmaceuticals Ltd Key Recent Developments

  • Jul 14,2023: CLINUVEL Secures IP For Melanocortins To Treat Central Nervous System Disorders
  • Apr 29,2022: Letter to shareholders from CLINUVEL’s CEO
  • Apr 04,2022: CLINUVEL appoints new non-executive director
  • Feb 16,2022: Clinuvel Pharmaceuticals to Announce Financial Results Half Year Ended, 31 December 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Clinuvel Pharmaceuticals Ltd - Key Facts
  • Clinuvel Pharmaceuticals Ltd - Key Employees
  • Clinuvel Pharmaceuticals Ltd - Key Employee Biographies
  • Clinuvel Pharmaceuticals Ltd - Major Products and Services
  • Clinuvel Pharmaceuticals Ltd - History
  • Clinuvel Pharmaceuticals Ltd - Company Statement
  • Clinuvel Pharmaceuticals Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Clinuvel Pharmaceuticals Ltd - Business Description
  • Geographical Segment: Europe and USA
  • Performance
  • Geographical Segment: Switzerland, Others
  • Performance
  • R&D Overview
  • Clinuvel Pharmaceuticals Ltd - Corporate Strategy
  • Clinuvel Pharmaceuticals Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Clinuvel Pharmaceuticals Ltd - Strengths
  • Clinuvel Pharmaceuticals Ltd - Weaknesses
  • Clinuvel Pharmaceuticals Ltd - Opportunities
  • Clinuvel Pharmaceuticals Ltd - Threats
  • Clinuvel Pharmaceuticals Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Recent Developments
  • Jul 14, 2023: CLINUVEL Secures IP For Melanocortins To Treat Central Nervous System Disorders
  • Apr 29, 2022: Letter to shareholders from CLINUVEL’s CEO
  • Apr 04, 2022: CLINUVEL appoints new non-executive director
  • Feb 16, 2022: Clinuvel Pharmaceuticals to Announce Financial Results Half Year Ended, 31 December 2021
  • Jan 10, 2022: Clinuvel's Growth and Expansion - H.C. Wainwright Bioconnect Conference 2022
Section 5 - Appendix
  • Methodology
  • Ratio Definitions
  • Contact Us
  • Disclaimer
List of Tables
  • Clinuvel Pharmaceuticals Ltd, Key Facts
  • Clinuvel Pharmaceuticals Ltd, Key Employees
  • Clinuvel Pharmaceuticals Ltd, Key Employee Biographies
  • Clinuvel Pharmaceuticals Ltd, Major Products and Services
  • Clinuvel Pharmaceuticals Ltd, History
  • Clinuvel Pharmaceuticals Ltd, Other Locations
  • Clinuvel Pharmaceuticals Ltd, Subsidiaries
  • Clinuvel Pharmaceuticals Ltd, Key Competitors
  • Clinuvel Pharmaceuticals Ltd, Ratios based on current share price
  • Clinuvel Pharmaceuticals Ltd, Annual Ratios
  • Clinuvel Pharmaceuticals Ltd, Interim Ratios
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Clinuvel Pharmaceuticals Ltd, Performance Chart (2019 - 2023)
  • Clinuvel Pharmaceuticals Ltd, Ratio Charts

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Biosensis Pty Ltd
  • EnGeneIC Ltd
  • Opthea Ltd
  • Rhinomed Ltd
  • EnGeneIC Ltd
  • MEI Pharma Inc
  • Immune System Therapeutics Ltd
  • Rhinomed Ltd
  • Opthea Ltd
  • Immune System Therapeutics Ltd
  • MEI Pharma Inc
  • biosensis Pty Ltd